Sunesis Pharmaceuticals (FRA:RYIS) Additional Paid-In Capital : €590.85 Mil(As of Dec. 2020)

View and export this data going back to 2007. Start your Free Trial

What is Sunesis Pharmaceuticals Additional Paid-In Capital?

Sunesis Pharmaceuticals's quarterly additional paid-in capital declined from Jun. 2020 (€620.97 Mil) to Sep. 2020 (€610.03 Mil) but then stayed the same from Sep. 2020 (€610.03 Mil) to Dec. 2020 (€590.85 Mil).

Sunesis Pharmaceuticals's annual additional paid-in capital increased from Dec. 2018 (€564.72 Mil) to Dec. 2019 (€628.72 Mil) but then declined from Dec. 2019 (€628.72 Mil) to Dec. 2020 (€590.85 Mil).

Sunesis Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Sunesis Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunesis Pharmaceuticals Additional Paid-In Capital Chart

Sunesis Pharmaceuticals Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Additional Paid-In Capital

Get a 7-Day Free Trial

568.45

535.25

564.72

628.72

590.85

Sunesis Pharmaceuticals Quarterly Data
	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20
Additional Paid-In Capital	Get a 7-Day Free Trial															628.72	632.49	620.97	610.03	590.85

Sunesis Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Sunesis Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Sunesis Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunesis Pharmaceuticals (FRA:RYIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunesis Pharmaceuticals Inc (FRA:RYIS) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

395 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

http://www.sunesis.com

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Sunesis Pharmaceuticals (FRA:RYIS) Headlines

No Headlines